Adverum Biotechnologies, INC

Adverum Biotechnologies, Inc. has completed its merger with Flying Tigers Acquisition Corporation, a wholly-owned subsidiary of Eli Lilly and Company, following a successful tender offer.

Adverum Biotechnologies announced positive two-year follow-up data from its LUNA Phase 2 clinical trial for Ixo-vec in wet AMD, demonstrating significant reduction in injection burden and sustained visual and anatomic control.

Adverum Biotechnologies, Inc. terminated a long-term lease, incurring a $7.4 million promissory note, and announced the completion of patient enrollment for its pivotal Phase 3 ARTEMIS trial for Ixo-vec.

Eli Lilly and Company announced a definitive agreement to acquire Adverum Biotechnologies, Inc. for an upfront cash payment and contingent value rights tied to its lead gene therapy candidate, Ixo-vec.

Adverum Biotechnologies announced accelerated timelines for its pivotal Phase 3 ARTEMIS trial of Ixo-vec for wet AMD, with screening completed ahead of schedule and full enrollment and topline data expected sooner.

Adverum Biotechnologies reports Q2 2025 financial results, highlights strong ARTEMIS Phase 3 trial enrollment, and announces a $10 million private placement.

Adverum Biotechnologies announced a definitive merger agreement with Eli Lilly and Company, alongside reporting significant Q3 operating losses and ongoing clinical trial progress for its lead gene therapy candidate, Ixo-vec.

Adverum Biotechnologies reports increased losses and substantial doubt about its ability to continue as a going concern, despite advancing its lead gene therapy candidate Ixo-vec into Phase 3 trials and securing a $10 million private placement.

Adverum Biotechnologies announces its Q1 2025 financial results, highlighting progress in its Ixo-vec clinical trials while acknowledging substantial doubt about its ability to continue as a going concern without additional funding.

Adverum Biotechnologies reports a net loss of $27.1 million for the third quarter of 2024, while progressing its lead product candidate, Ixo-vec, towards Phase 3 clinical trials.

Adverum Biotechnologies reports a net loss of $18.5 million for the second quarter of 2024, while highlighting progress in its Ixo-vec clinical program and financial stability.

Adverum Biotechnologies reports a net loss of $24.8 million for the first quarter of 2024, while highlighting progress in its clinical programs and a strengthened cash position.

Adverum Biotechnologies' 10-K filing reveals substantial doubt about its ability to continue as a going concern due to recurring losses, a material weakness in internal controls, and the need for additional funding.

Adverum Biotechnologies' 2023 annual report details progress in its gene therapy programs, particularly for wet AMD, and outlines financial strategies for continued development.

Adverum Biotechnologies CEO Laurent Fischer reports significant changes in beneficial ownership following the company's acquisition by Eli Lilly and Company, involving cash and contingent value rights.

Adverum Biotechnologies' COO, Peter Soparkar, reported the disposition of common stock, RSUs, PSUs, and stock options following the company's acquisition by Eli Lilly and Company.

Adverum Biotechnologies, Inc. has completed its merger with Eli Lilly and Company, with shareholders receiving cash and contingent value rights.

Adverum Biotechnologies' Chief Development Officer reports changes in beneficial ownership following the company's acquisition by Eli Lilly and Company, converting shares, RSUs, PSUs, and options into cash and contingent value rights.

Adverum Biotechnologies' CFO, Linda M. Rubinstein, reported significant stock and option transactions following the company's acquisition by Eli Lilly and Company, effective December 9, 2025.

Adverum Biotechnologies Director Soo Hong's stock options were cancelled following the company's merger with Eli Lilly and Company's subsidiary, Flying Tigers Acquisition Corporation.

Adverum Biotechnologies, Inc. has issued a supplement to its proxy statement, introducing more restrictive parameters for its proposed stock option repricing, including a longer service period and higher exercise price thresholds, aiming to garner stockholder approval at the upcoming Annual Meeting on June 17, 2025.

Adverum Biotechnologies, Inc. has filed a definitive proxy statement with the SEC.

Adverum Biotechnologies is holding its 2025 Annual Meeting of Stockholders on June 17, 2025, to vote on director elections, auditor ratification, executive compensation, and equity incentive plan amendments.

Adverum Biotechnologies announces the appointment of Rabia Gurses Ozden, M.D. as Chief Medical Officer and Szilrd Kiss, M.D. as a new director, effective June 10, 2024.

Adverum Biotechnologies updates its non-employee director compensation policy, adjusting cash and equity compensation based on the company's market capitalization.

Adverum Biotechnologies has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

BML Investment Partners and Braden M. Leonard have fully divested their beneficial ownership in Adverum Biotechnologies, Inc. common stock.

BML Investment Partners and Braden M. Leonard have reduced their beneficial ownership in Adverum Biotechnologies, Inc. to an aggregate of 9.7% after selling over 1 million shares.

BML Investment Partners and Braden M. Leonard, holding 15.6% of Adverum Biotechnologies, express deep disappointment with the Eli Lilly merger terms and the board's handling of the sale process.

BML Investment Partners, L.P. and Braden M. Leonard have disclosed a combined beneficial ownership of 15.6% in Adverum Biotechnologies, Inc., acquired for investment purposes with potential for future strategic discussions.

Frazier Life Sciences and related entities have reported a complete divestment of their beneficial ownership in Adverum Biotechnologies, Inc., now holding 0.0% of common stock.

Frazier Life Sciences funds updated their beneficial ownership in Adverum Biotechnologies, Inc., with Frazier Life Sciences Public Fund, L.P. holding 19.4%.

Frazier Life Sciences entities filed an amended Schedule 13G, detailing their beneficial ownership and warrant holdings in Adverum Biotechnologies, Inc.

Franklin Resources, Inc. and its principals report zero beneficial ownership in Adverum Biotechnologies, Inc., signaling a complete divestment.

BlackRock, Inc. has disclosed a 2.0% passive beneficial ownership stake in Adverum Biotechnologies, Inc., holding 414,485 shares of common stock as of June 30, 2025.

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have jointly disclosed a passive beneficial ownership of 8.9% in Adverum Biotechnologies, Inc., totaling 1,871,482 shares.